View in EDS

Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma.

Saved in:
Bibliographic Details
Title: Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma.
Authors: Campbell KM; Division of Hematology/Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA. Electronic address: katiecampbell@mednet.ucla.edu., Amouzgar M; Department of Pathology, Stanford University, Stanford, CA 94305, USA; Parker Institute for Cancer Immunotherapy, San Francisco, CA 94129, USA., Pfeiffer SM; Parker Institute for Cancer Immunotherapy, San Francisco, CA 94129, USA., Howes TR; Parker Institute for Cancer Immunotherapy, San Francisco, CA 94129, USA., Medina E; Division of Hematology/Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA., Travers M; Parker Institute for Cancer Immunotherapy, San Francisco, CA 94129, USA., Steiner G; Parker Institute for Cancer Immunotherapy, San Francisco, CA 94129, USA., Weber JS; Perlmutter Cancer Center, NYU School of Medicine, New York, NY 10016, USA., Wolchok JD; Parker Institute for Cancer Immunotherapy, San Francisco, CA 94129, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Weill Cornell Medicine, New York, NY 10065, USA., Larkin J; Department of Medical Oncology, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK., Hodi FS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Boffo S; Bristol Myers Squibb Corp., Princeton, NJ 08540, USA., Salvador L; Bristol Myers Squibb Corp., Princeton, NJ 08540, USA., Tenney D; Bristol Myers Squibb Corp., Princeton, NJ 08540, USA., Tang T; Bristol Myers Squibb Corp., Princeton, NJ 08540, USA., Thompson MA; Parker Institute for Cancer Immunotherapy, San Francisco, CA 94129, USA., Spencer CN; Parker Institute for Cancer Immunotherapy, San Francisco, CA 94129, USA., Wells DK; Parker Institute for Cancer Immunotherapy, San Francisco, CA 94129, USA., Ribas A; Division of Hematology/Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA; Parker Institute for Cancer Immunotherapy, San Francisco, CA 94129, USA; Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA 90095, USA; Division of Surgical Oncology, Department of Surgery, University of California, Los Angeles, Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA 90024, USA. Electronic address: aribas@mednet.ucla.edu.
Source: Cancer cell [Cancer Cell] 2023 Apr 10; Vol. 41 (4), pp. 791-806.e4.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
Journal Info: Publisher: Cell Press Country of Publication: United States NLM ID: 101130617 Publication Model: Print Cited Medium: Internet ISSN: 1878-3686 (Electronic) Linking ISSN: 15356108 NLM ISO Abbreviation: Cancer Cell Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 37037616
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Campbell+KM%22">Campbell KM</searchLink>; Division of Hematology/Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA. Electronic address: katiecampbell@mednet.ucla.edu.<br /><searchLink fieldCode="AU" term="%22Amouzgar+M%22">Amouzgar M</searchLink>; Department of Pathology, Stanford University, Stanford, CA 94305, USA; Parker Institute for Cancer Immunotherapy, San Francisco, CA 94129, USA.<br /><searchLink fieldCode="AU" term="%22Pfeiffer+SM%22">Pfeiffer SM</searchLink>; Parker Institute for Cancer Immunotherapy, San Francisco, CA 94129, USA.<br /><searchLink fieldCode="AU" term="%22Howes+TR%22">Howes TR</searchLink>; Parker Institute for Cancer Immunotherapy, San Francisco, CA 94129, USA.<br /><searchLink fieldCode="AU" term="%22Medina+E%22">Medina E</searchLink>; Division of Hematology/Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.<br /><searchLink fieldCode="AU" term="%22Travers+M%22">Travers M</searchLink>; Parker Institute for Cancer Immunotherapy, San Francisco, CA 94129, USA.<br /><searchLink fieldCode="AU" term="%22Steiner+G%22">Steiner G</searchLink>; Parker Institute for Cancer Immunotherapy, San Francisco, CA 94129, USA.<br /><searchLink fieldCode="AU" term="%22Weber+JS%22">Weber JS</searchLink>; Perlmutter Cancer Center, NYU School of Medicine, New York, NY 10016, USA.<br /><searchLink fieldCode="AU" term="%22Wolchok+JD%22">Wolchok JD</searchLink>; Parker Institute for Cancer Immunotherapy, San Francisco, CA 94129, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Weill Cornell Medicine, New York, NY 10065, USA.<br /><searchLink fieldCode="AU" term="%22Larkin+J%22">Larkin J</searchLink>; Department of Medical Oncology, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.<br /><searchLink fieldCode="AU" term="%22Hodi+FS%22">Hodi FS</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.<br /><searchLink fieldCode="AU" term="%22Boffo+S%22">Boffo S</searchLink>; Bristol Myers Squibb Corp., Princeton, NJ 08540, USA.<br /><searchLink fieldCode="AU" term="%22Salvador+L%22">Salvador L</searchLink>; Bristol Myers Squibb Corp., Princeton, NJ 08540, USA.<br /><searchLink fieldCode="AU" term="%22Tenney+D%22">Tenney D</searchLink>; Bristol Myers Squibb Corp., Princeton, NJ 08540, USA.<br /><searchLink fieldCode="AU" term="%22Tang+T%22">Tang T</searchLink>; Bristol Myers Squibb Corp., Princeton, NJ 08540, USA.<br /><searchLink fieldCode="AU" term="%22Thompson+MA%22">Thompson MA</searchLink>; Parker Institute for Cancer Immunotherapy, San Francisco, CA 94129, USA.<br /><searchLink fieldCode="AU" term="%22Spencer+CN%22">Spencer CN</searchLink>; Parker Institute for Cancer Immunotherapy, San Francisco, CA 94129, USA.<br /><searchLink fieldCode="AU" term="%22Wells+DK%22">Wells DK</searchLink>; Parker Institute for Cancer Immunotherapy, San Francisco, CA 94129, USA.<br /><searchLink fieldCode="AU" term="%22Ribas+A%22">Ribas A</searchLink>; Division of Hematology/Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA; Parker Institute for Cancer Immunotherapy, San Francisco, CA 94129, USA; Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA 90095, USA; Division of Surgical Oncology, Department of Surgery, University of California, Los Angeles, Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA 90024, USA. Electronic address: aribas@mednet.ucla.edu.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101130617%22">Cancer cell</searchLink> [Cancer Cell] 2023 Apr 10; Vol. 41 (4), pp. 791-806.e4.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Cell+Press%22">Cell Press </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101130617 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1878-3686 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2215356108%22">15356108 </searchLink><i>NLM ISO Abbreviation: </i>Cancer Cell <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=37037616
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.ccell.2023.03.010
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 791
    Titles:
      – TitleFull: Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Campbell KM
      – PersonEntity:
          Name:
            NameFull: Amouzgar M
      – PersonEntity:
          Name:
            NameFull: Pfeiffer SM
      – PersonEntity:
          Name:
            NameFull: Howes TR
      – PersonEntity:
          Name:
            NameFull: Medina E
      – PersonEntity:
          Name:
            NameFull: Travers M
      – PersonEntity:
          Name:
            NameFull: Steiner G
      – PersonEntity:
          Name:
            NameFull: Weber JS
      – PersonEntity:
          Name:
            NameFull: Wolchok JD
      – PersonEntity:
          Name:
            NameFull: Larkin J
      – PersonEntity:
          Name:
            NameFull: Hodi FS
      – PersonEntity:
          Name:
            NameFull: Boffo S
      – PersonEntity:
          Name:
            NameFull: Salvador L
      – PersonEntity:
          Name:
            NameFull: Tenney D
      – PersonEntity:
          Name:
            NameFull: Tang T
      – PersonEntity:
          Name:
            NameFull: Thompson MA
      – PersonEntity:
          Name:
            NameFull: Spencer CN
      – PersonEntity:
          Name:
            NameFull: Wells DK
      – PersonEntity:
          Name:
            NameFull: Ribas A
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 10
              M: 04
              Text: 2023 Apr 10
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-electronic
              Value: 1878-3686
          Numbering:
            – Type: volume
              Value: 41
            – Type: issue
              Value: 4
          Titles:
            – TitleFull: Cancer cell
              Type: main
ResultId 1